Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2007 by Inje University. Recruitment status was Recruiting

First Received on June 26, 2007. Last Updated on August 7, 2007 History of Changes

Sponsor:	Inje University
Collaborator:	GlaxoSmithKline
Information provided by:	Inje University
ClinicalTrials.gov Identifier:	NCT00492414

Purpose

Panic disorder(PD)is a disabling psychiatric condition associated with significant impairment in psychosocial, occupational functioning and quality of life, as mentioned by mogotsi et al. So, most patients with panic disorder suffers from the consequences of the impairment in occupational function. This impairment is not only individual problem, but also social one. Since productivity is very important item required to employees, lost productive time among workers with psychiatric illness should be reduced by the proper management. But few data were reported in this field by now.

Condition	Intervention	Phase
Panic Disorder	Drug: Paroxetine CR	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Health Services Research

Resource links provided by NLM:

MedlinePlus related topics: Panic Disorder

Drug Information available for: Paroxetine Paroxetine hydrochloride Paroxetine hydrochloride hemihydrate Paroxetine Mesylate

U.S. FDA Resources

Further study details as provided by Inje University:

Eligibility

Ages Eligible for Study:	20 Years to 50 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Male or female outpatients aged 20-50 years
In female, is eligible to enter this study if she is if
- Non-childbearing potential(note:women who are 6 months post-menopausal are not considered women of child-bearing potential)
- child-bearing potential, has a negative urine dipstick pregnancy test, and is practicing a clinically acceptable method of contraception such as oral contraception, surgical sterilization, I.U.D.,systemic contraception, or double barrier contraception(any two of diaphragm/spermicidal foar/condom)
Subject currently meets the diagnosis for PD according to korean version of Anxiety Disorder Interview Schedule for DSM-IV(ADIS-IV) through a comprehensive psychiatric evaluation and not being treated currently.
Subject must have the ability to comprehend the key components of the consent form and provide informed consent.

Exclusion Criteria:

Subject who has a history of any other major medical or psychiatric illnesses except PD or PD with major depressive disorder.
Subject who retired or left his job or who plan to retire within two years.
is a current homicidal or suicidal risk in the investigator's judgement.
is currently pregnant, lactating or planning to become pregnant within the next 3 months
is currently participating in any other clinical trial or taking any non-approved or experimental medication.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492414

Contacts

Contact: Eun-Joo Jung

+82-2-2270-0940

menfipro@naver.com

Locations

Korea, Republic of
Seoul Paik Hospital, Inje University	Recruiting
Seoul, Korea, Republic of
Contact: Eun-Joo Jung +82-2-2270-0940 menfipro@naver.com

Sponsors and Collaborators

Inje University

GlaxoSmithKline

Investigators

Principal Investigator:

Jong-Min Woo, Master

Seoul Paik Hospital, Inje University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00492414 History of Changes
Other Study ID Numbers:	COL110010
Study First Received:	June 26, 2007
Last Updated:	August 7, 2007
Health Authority:	South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Inje University:

Panic disorder (PD)

Additional relevant MeSH terms:

Panic Disorder
Anxiety Disorders
Mental Disorders
Paroxetine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 13, 2012